

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/72, B65D 83/14		A1	(11) International Publication Number: WO 98/24420
			(43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/GB97/03360			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 4 December 1997 (04.12.97)			
(30) Priority Data: 9625171.5 4 December 1996 (04.12.96) GB 9626449.4 20 December 1996 (20.12.96) GB			
(71) Applicant (for all designated States except US): BIOGLAN IRELAND (R & D) LIMITED [IE/IE]; Unit 5, 151 Baldoyle Industrial Estate, Dublin 13 (IE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MCCARTHY, Paul [IE/IE]; Ballyvaughan, Clonmel, County Tipperary (IE). GOODMAN, Michael [GB/GB]; 30 Rushbrook Close, Ampthill, Bedfordshire MK45 2XE (GB). LINDAHL, Åke [SE/SE]; Ringduvevägen 50, S-274 33 Skurup (SE).			
(74) Agent: JUMP, Timothy, John, Simon; Venner, Shipley & Co., 20 Little Britain, London EC1A 7DH (GB).			
(54) Title: PHARMACEUTICAL COMPOSITIONS AND DEVICES FOR THEIR ADMINISTRATION			
(57) Abstract			
<p>A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical composition including a pharmaceutically active agent in a solution of liquified 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alcohol, polyol, (poly)alkoxy derivative, fatty acid alkyl ester, polyalkylene glycol, or dimethyl sulphoxide. The device includes valve means arranged for delivering aerosol doses of said pharmaceutical composition to the exterior of the container, and at least a portion of the device is formed from a polyester.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITIONS AND DEVICES FOR
THEIR ADMINISTRATION

5

DESCRIPTION

The present invention relates to pharmaceutical compositions comprising a pharmaceutically active agent in liquified 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) as a propellant, for delivery in aerosol form, and to a device for delivering such a composition as an aerosol.

Most current aerosol spray formulations use one or more chlorofluorocarbon as a propellant; dichloro-difluoromethane being commonly used. However, chlorofluorocarbons have been implicated in the depletion of the ozone layer and their production, therefore, is being phased out. It has been found that certain hydrofluorocarbons, which are both of low toxicity and of suitable vapour pressure for use as aerosol propellants, are significantly less harmful to the ozone layer. Among such hydrofluorocarbons, 1,1,1,2-tetrafluoroethane (HFC-134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) have been proposed as suitable propellants for pharmaceutical aerosols.

It has now been found that HFC-134a and HFC-227 can be used in combination with many pharmaceutically active agents, without causing any degradation to them or reducing their physiological activity.

Devices for administering metered aerosol doses of pharmaceutical preparations are well known in the art. Such devices include those disclosed in WO 92/11190, US-A-4819834 and US-A-4407481. Many of these devices include metering valves having components formed from plastic materials, such as the valves available from Bepak PLC of Bergen Way, Kings Lynn, Norfolk PE30 2JJ, United Kingdom, in which the valve core, metering chamber and some other structural components are formed from plastic materials. The plastic materials currently used for forming these structural parts in valves employed with many chlorofluorocarbon containing formulations include certain acetal co-polymers.

Although the plastics employed to manufacture metering valves, including the aforementioned acetal co-polymers, have also been found to be stable in the presence of HFC-134a alone, the applicants, to their surprise, have determined that many of these plastics materials can be caused to swell in the presence of formulations which include certain carriers or active agent solubilising co-solvents with HFC-134a. When such swelling takes place in a valve, the fit of mutually slidable components, such as metering chambers and valve cores, is adversely effected and they can bind together or become loose, causing the valve to leak or cease functioning altogether.

This problem has now been solved in accordance with a first aspect of the invention by a device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical composition including a

pharmaceutically active agent in a solution of liquified HFC-134a, or HFC-227, and a carrier selected from pharmaceutically acceptable alcohols, polyols, (poly) alkoxy derivatives, fatty acid alkyl esters, polyalkylene glycols, and dimethylsulphoxide, and valve means arranged for delivering aerosol doses of
5 said pharmaceutical composition to the exterior of the container, wherein at least a portion of the device is formed from a polyester.

Preferably, the valve means includes at least one component formed from a polyester, which component, more preferably, is a metering chamber and/or a
10 valve core. Preferably, devices in accordance with the invention are arranged to provide metered doses of the pharmaceutically active agent included therein.

In further embodiments, the container comprises a polyester and, preferably,
15 consists of metal lined with a polyester. The canister cap can also be so formed.

Apart from allowing the aforementioned swelling problem to be solved, an advantage of this aspect of the present invention is that use of expensive metal
20 valve components can be avoided.

During the course of the work leading to this aspect of the present invention, tests carried out on active agent/carrier or co-solvent/HFC-134a filled metered dose aerosol devices, with acetyl copolymer or nylon valve components,

showed that they failed to provide uniform doses after storage under controlled conditions. Such effects are normally associated with problems involving the gaskets or seals employed within the valve mechanisms. Thus, it came as a surprise to the applicants when they discovered that these failures
5 were being caused by the valve components swelling to an unacceptable extent, particularly since at least one of the materials used to form them (acetyl co-polymer) was known to be stable in the presence of HFC-134a alone, or conventional active agent/carrier or co-solvent/chlorofluorocarbon formulations.

10

The preferred polyesters are polyalkylene benzene dicarboxylates, more preferably polyalkylene terephthalates and, most preferably, a polybutylene terephthalate.

15 Such materials, preferably, have a density of about 1.3g/cm³ and a water absorption of about 0.6% (23°C saturation). The polyesters, also, are preferably partially crystalline in nature and have a crystalline melting range of 220-225°C.

20 Examples of suitable polybutylene terephthalates include those available under the Trademark Celanex® from Hoechst UK Limited, Walton Manner, Milton Keynes, Bucks MK7 7AJ, United Kingdom. Particularly preferred are Celanex® 2500 and Celanex® X 500/2.

Preferably, the carrier is a lower alkyl (C_1 - C_4) alcohol, a polyol, or a (poly) alkoxy derivative. In embodiments, the carrier is a C_1 - C_4 alkyl alcohol or a lanolin alcohol and, preferably, is ethanol or isopropyl alcohol. The most preferred alcohol is ethanol.

5

The preferred polyols include propylene glycol and glycerol and the preferred (poly) alkoxy derivatives include polyalkoxy alcohols, in particular 2-(2-ethoxyethoxy) ethanol (available under the Trademark Transcutol®).

- 10 Further preferred (poly)alkoxy derivatives include polyoxyalkyl ethers and esters, such as polyoxyethylene ethers or esters. The preferred polyoxyethylene ethers and esters are polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates.

15

The preferred fatty acid alkyl esters are ethyl oleate, isopropyl myristate and isopropyl palmitate. The preferred polyalkylene glycol is polyethylene glycol.

- In preferred embodiments, the inventive composition can comprise up to 50% or, preferably, 25% w/w carrier. More preferred embodiments include between 3% and 15% w/w, or between 4 and 10% w/w carrier. The pharmaceutical compositions can comprise between 50% and 99% w/w, preferably between 75% and 99% w/w, and, more preferably, between 88% and 95% w/w HFC-134a or HFC-227.
- 20

In further embodiments, compositions used in the present invention can comprise a plurality of different carriers.

Further excipients can be included in the formulations employed in the present invention. For example, neutral oils as well as surfactants (the latter for aiding the smooth operation of the valve), as are well known to those skilled in the art, may be included.

Thus, in further preferred embodiments, compositions employed in the invention can comprise an organic surfactant. The preferred organic surfactant is oleyl alcohol, although others can be employed, including sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan mono-oleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, oleic acid, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate, glyceryl mono-oleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, cetyl pyridinium chloride, olive oil, glyceryl monolaurate, corn oil, cotton seed oil or sunflower seed oil.

The pharmaceutically active agent, preferably, is insoluble, or only sparingly soluble in pure liquified HFC-134a or HFC-227. Preferably, the solubility of the active agent in liquified HFC-134a or HFC-227 is from 3 to 0.001%w/v,

preferably from 1 to 0.01% w/v. However, in certain preferred embodiments, the solubility of the active agent in liquified HFC-134a or HFC-227 is from 3 to 1% w/v.

5 The preferred active agents include:-

- (1) steroid drugs such as, for example, beclomethasone, betamethasone, dexamethasone, fluticasone, hydrocortisone, budesonide, flunisolide, triamcinolone flumethasone, and prednisolone;
- (2) antibiotic and antibacterial agents such as, for example,
10 neomycin, mupirocin and chlorhexidine;
- (3) systemically active drugs such as, for example, isosorbide dinitrate, isosorbide mononitrate, apomorphine and nicotine;
- (4) antihistamines such as, for example, azelastine, chlorpheniramine, astemizole and terfenadine;
- 15 (5) anti-inflammatory agents such as, for example, piroxicam, nedocromil, cromoglycate, fasafungine and iodoxamide;
- (6) anticholinergic agents such as, for example, ipratropium bromide and oxitropium bromide;
- (7) anti-emetics such as, for example, domperidone, hyoscine,
20 cinnarizine metoclopramide, cyclizine, dimenhydrinate and promethazine;
- (8) hormonal drugs such as, for example, vasopressin or desmopressin;
- (9) bronchodilators, such as salbutamol, fenoterol and salmeterol;

- (10) sympathomimetic drugs, such as tramazoline and xylometazoline;
- (11) Anti-fungal drugs such as miconazole;
- (12) Local anaesthetics such as benzocaine and lignocaine; and
- 5 (13) pharmaceutically acceptable salts of any of the foregoing.

Of these, the most preferred pharmaceutically active agent is beclomethasone dipropionate. Beclomethasone dipropionate may be employed in an anhydrous, hydrated or solvated state but, preferably, is employed in an
10 anhydrous state. The preferred propellant is HFC-134a.

Preferably, the pharmaceutical composition includes a solution of the pharmaceutically active agent in HFC-134a or HFC-227, with the carrier as a co-solvent. It is further preferred that the co-solvent solubilises the active
15 agent, in the sense that its presence increases the solubility of the active agent in the composition and, thus, causes or allows all or a proportion of the active agent present in the composition to dissolve and/or remain in solution.

The pharmaceutical compositions can be partial solutions in which only a
20 proportion of the pharmaceutically active agent present therein is dissolved in the propellant and co-solvent, with the remainder being in suspension or suspendible. The exact proportions of dissolved and suspended active agent will depend upon the active agent concerned, its concentration and the identity and quantity of the co-solvent(s) used. In preferred embodiments the

compositions are in the form of liquid solutions when maintained under pressure in devices in accordance with the invention.

A particularly preferred embodiment of the invention comprises a device in
5 accordance with the first aspect of the invention filled with a solution of beclomethasone, preferably beclomethasone dipropionate, in ethanol as a co-solvent and HFC-134a as a propellant.

Devices and formulations in accordance with the invention can be used to
10 provide sprays suitable for nasal, or sublingual administration, or for inhalation. Preferably, the compositions of this invention are formulated for administration to the nasal passages or the sublingual mucosa and devices in accordance with the invention are arranged for providing a spray of the inventive composition to either of the latter locations.

15

In embodiments wherein the composition is intended for sublingual administration, it can further comprises a flavouring oil such as, for example peppermint oil Ph Eur.

20 In a second aspect, the invention provides the use of a polyester in contact with a composition of the type present in devices in accordance with the first aspect of the invention. Preferably the polyester is one of those described above, and the use takes place in a metered dose dispensing aerosol device.

An embodiment of the first aspect of the present invention will now be described, by way of example only, and with reference to the following drawing.

5 Figure 1 is a cross sectional view of an embodiment of a device in accordance with the invention.

The device 1 comprises a substantially cylindrical canister 2 sealed with a cap 3. Both the canister 2 and the cap 3 are formed from an aluminium alloy and
10 can be lined with a polyester (such as Celanex® 2500) or a lacquer (not shown).

A valve body moulding 4 comprises a cylindrical portion 5, which defines a metering chamber 6 and a stepped flange portion 7, and is formed by injection
15 moulding from Celanex® 2500. The stepped flange portion 7 defines a first and outwardly facing annular seat 8 and a second, inwardly facing annular seat 9. The first annular seat 8 accommodates an annular sealing ring 10 and the second annular seat 9 accommodates a first sealing washer 11. The first
sealing washer 11 is located so as to cooperate with the cylindrical portion 5
20 of the valve body moulding 4, in defining the metering chamber 6.

A base 12 of the cylindrical portion 5 of the valve body moulding 4 completes the boundary to the metering chamber 6 and provides a seat for a second sealing washer 13.

The sealing ring 10 and the first and second sealing washers 11 and 13 can be formed from a butyl rubber, neoprene or one of the elastomers disclosed for such purposes in WO 92/11190.

- 5 An elongate, substantially cylindrical and partially hollow valve core 14 is slidably located within the first and second sealing washers 11 and 13 and extends through an orifice 15, defined in the base 12. The valve core 14 is formed by injection moulding from Celanex® 2500.
- 10 A stepped inlet passage 16 communicates between a first end 17 of the valve core 14 and an inlet orifice 18, formed through the side of the valve core 14. In a likewise manner, an outlet passage 19 communicates between the second end 20 of the valve core 14 and an outlet orifice 21 formed through the side of the valve core 14. An annular flange 22 extends radially outwardly from
- 15 the valve core 14 between the inlet and outlet orifices 18 and 21 and adjacent to the outlet orifice 21.

- A stainless steel compression coil spring 23 acts between the annular flange 22 and the second sealing washer 13, urging the annular flange 22 into contact
- 20 with the first sealing washer 11, such that the outlet orifice 21 lies inside the first sealing washer 11 and is thereby isolated from the metering chamber 6. In this position, as shown in Figure 1, the inlet orifice 18 is located within the metering chamber 6. A flexible tube 24 is engaged within the stepped inlet passage 16 and extends from the valve core 14 to the base of the canister 2 (as

- 12 -

shown in Figure 1). Thus, the inlet orifice 18 is in communication with a region within the canister 2 adjacent to its base 12.

The cap 3 is firmly attached to the canister 2 by crimping and, thus, holds the assembly of the valve body moulding 4, valve core 14, coil spring 23, sealing washers 11 and 13 and sealing ring 10 in place as shown in Figure 1, with the sealing ring 10 and first sealing washer 11 sufficiently compressed to seal the interior of the device 1 and prevent the egress of its contents.

Downward movement of the valve core, in the direction of arrow A, against the action of the spring 22 will bring the outlet orifice 21 into the metering chamber immediately after the first orifice 18 has been sealed from the metering chamber 6 by the second sealing washer 13.

When filled with a composition in accordance with the present invention, as shown at 25, the device 1 will provide metered doses of the composition when used as follows. The device 1 should be held in the position shown in Figure 1, so that the composition 25, by virtue of its pressure, enters the metering chamber 6 via the tube 24, the inlet passage 16 and the inlet orifice 18.

Subsequent depression of the valve core 14, in the direction of arrow A, seals the inlet orifice 18 and hence the remainder of the canister 2, from the metering chamber 6 and opens the outlet passage to the metering chamber 6, via the outlet orifice 21. Since the composition 25 in the metering chamber 6 is pressurised with the propellant, it will be expelled from the metering chamber 6 through the outlet orifice 21 and the outlet passage 19. If the valve

- 13 -

core 14 is then allowed to return to the position shown in Figure 1, under the influence of the spring 22, the outlet orifice 21 is again sealed from the metering chamber 6 and the metering chamber 6 will be filled with pressurised composition 25 from the canister 2, via the tube 24, stepped inlet
5 passage 16 and inlet orifice 18.

Example 1

A composition comprising beclomethasone dipropionate (BDP) with HFC-134a suitable for use in a device as described above was formulated from the
10 following ingredients:-

<u>Component</u>	<u>percent w/w</u>	<u>g/can</u>
BDP (anhydrous)	0.164	0.010
Ethanol 96% BP	4.992	0.305
HFC-134a	94.844	5.795
15 Total	100	6.11

The BDP was dissolved in the ethanol in the proportions set out above and 0.315 g of the resulting solution was then placed in a canister 2 and a valve assembly, comprising a valve body moulding 4, first sealing washer 11, second
20 sealing washer 13, spring 22, tube 23, and annular seal 10, was then sealed onto the canister 2 by crimping as shown in Figure 1 by the cap 3. The propellant (HFC-134a) was then added to the canister, by being forced through the valve core 14 at great pressure, and the complete device was then checked for leaks. After the propellant entered the canister it dissolved the

remaining portions of the composition.

In a preferred embodiment, each expelled dose of the above formulation is of approximately 25 μ l and provides 50 μ g of BDP.

5

Example 2

A second composition comprising BDP and suitable for use in a device as described above was formulated from the following ingredients:-

10	<u>Component</u>	<u>percent w/w</u>	<u>g/can</u>
	BDP (anhydrous)	0.164	0.010
	Ethanol 96% BP	7.5	0.458
	HFC-134a	92.336	5.641
	Total	100	6.11

15

The BDP was dissolved in the ethanol in the proportions set out above and 0.315g of the resulting solution was then placed in a canister 2. A valve assembly (as described in Example 1) was then sealed onto the canister 2 by crimping and the HFC-134a propellant was then added to the canister, by
20 being forced through the valve core 14 at great pressure, and the complete device was then checked for leaks. After the propellant entered the canister it dissolved the remaining portions of the composition.

In a preferred embodiment, each expelled dose of the above formulation is

approximately 25 μ l and provides 50 μ l of BDP.

Example 3

Further compositions comprising BDP with HFC-134a, suitable for use in a
5 device as described herein, were formulated in accordance with the details set
out in the following table, in which all figures are given on a percent by
weight basis.

Formulation	A	B	C	D	E
BDP	0.164	0.164	0.164	0.164	0.164
10 Transcatol	9.984	4.992			
Oleyl alcohol			2.496		
Propylene glycol				4.992	
Ethanol		4.992	7.488	4.992	20.51
p134a	89.852	89.852	89.852	89.852	79.326
15 Total	100	100	100	100	100

Formulations A-E are prepared using a similar technique to that set out in
example 1 above. Briefly, the BDP is dissolved with the other excipient or
excipients (excepting the HFC-134a) and the resulting solution is then placed
20 in a canister 2. A valve assembly is then sealed onto the canister 2 by
crimping and the HFC-134a propellant is then added to the canister 2, by
being forced through the valve core 14 at great pressure. After the propellant
enters the canister 2, it dissolves the remaining portions of each composition.

Although only BDP is referred to in this example, other ones of the active agents previously discussed in this application may be substituted therefor in quantities which would dissolve at least partially in the propellant/co-solvent mixture.

5

Examples 4-11

Eight further compositions suitable for use in a device as described herein, were formulated in accordance with the details set out in the following table.

10	<u>Example</u>	<u>Component</u>	<u>Percent w/w</u>
	<u>Example 4</u>	Mupirocin	0.1
		Tween 20	0.1
		Ethanol	20.0
		HFC-134a	79.8
15	<u>Example 5</u>	Isosorbide Dinitrate	1.0
		Propylene Glycol	3.0
		Peppermint Oil Ph Eur	1.0
		Ethanol	15.0
20		HFC-134a	80.0

<u>Example 6</u>	Cromoglycate	0.2
------------------	--------------	-----

	Span 5	0.1
	Ethanol	20.0
	HFC-134a	79.7
5	<u>Example 7</u>	
	Domperidone	0.2
	Oleyl alcohol	0.1
	Transcutol	4.0
	Ethanol	10.0
	HFC-134a	84.7
10		
	<u>Example 8</u>	
	Salbutamol	0.2
	Oleic acid	0.01
	Miglyol 840	2.0
	Ethanol	10.0
15	HFC-134a	87.89
	<u>Example 9</u>	
	Xylometazoline	0.1
	Oleic acid	0.01
	Propylene glycol	3.0
20	Ethanol	12.0
	HFC-134a	84.89
	<u>Example 10</u>	
	Miconazole	1.0

- 18 -

Oleic acid	0.1
Transcutol	4.0
Ethanol	16.0
HFC-134a	78.9

5

Example 11

Benzocaine	1.0
PEG 400	4.0
Ethanol	5.0
HFC-134a	90.0

10

These compositions are prepared using a similar technique to that set out in Examples 1-2. Briefly, the active agent is mixed with the other excipient or excipients (excepting the HFC-134a) and the resulting solution and/or suspension is then placed in a canister 2. A valve assembly (as described in Example 1) is then sealed onto the canister 2 by crimping and the HFC-134a propellant is then added to the canister, by being forced through the valve core 14 at great pressure. After the propellant enters the canister 2, it at least partially and in some cases completely dissolves the remaining portions of each composition.

20

CLAIMS

1. A device for providing pharmaceutical doses comprising a container,
filled with a pharmaceutical composition including a pharmaceutically active
5 agent in a solution of liquified 1,1,1,2-tetrafluoroethane (HFC-134a), or
1,1,1,2,3,3,3-heptafluoropropane (HFC-227), and a carrier selected from
pharmaceutically acceptable alcohols, polyols, (poly) alkoxy derivatives, fatty
acid alkyl esters, polyalkylene glycols, and dimethyl sulphoxide, and valve
means arranged for delivering aerosol doses of said pharmaceutical
10 composition to the exterior of the container, wherein at least a portion of the
device is formed from a polyester.
2. A device as claimed in claim 1, wherein the carrier, is a C₁-C₄ lower
alkyl alcohol or a lanolin alcohol and is preferably ethanol or isopropyl
15 alcohol.
3. A device as claimed in claim 2, wherein the carrier is ethanol.
4. A device as claimed in claim 1, wherein the carrier is propylene glycol
20 or glycerol.
5. A device as claimed in claim 1, wherein the carrier is a polyalkoxy
alcohol and is preferably 2-(2-ethoxy ethoxy)ethanol (Transcutol).

6. A device as claimed in claim 1, wherein the carrier is a polyoxyalkyl ether or ester, and is preferably a polyoxyethylene ether or ester.
7. A device as claimed in claim 6, wherein the carrier is a
5 polyoxyethylene alkyl ether, a polyoxyethylene castor oil derivative, a polyoxyethylene sorbitan fatty acid ester or a polyoxyethylene stearate.
8. A device as claimed in claim 1, wherein the carrier is ethyl oleate, isopropyl myristate or isopropyl palmitate.
- 10
9. A device as claimed in claim 1, wherein the carrier is polyethylene glycol.
10. A device as claimed in any of the preceding claims wherein the
15 composition comprises up to 50% w/w, preferably up to 25% w/w carrier.
11. A device as claimed in any of the preceding claims wherein the composition comprises between 50 and 99% w/w and, preferably, between 75 and 95% w/w HFC-134a or HFC-227.
- 20
12. A device as claimed in any of the preceding claims, wherein the composition comprises a plurality of carriers.
13. A device as claimed in any of the preceding claims, wherein the

composition further comprises an organic surfactant.

14. A device as claimed in claim 13, wherein the organic surfactant is oleyl alcohol, sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate,
5 polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan mono-oleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, oleic acid, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate,
10 glyceryl mono-oleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, cetyl pyridinium chloride, olive oil, glyceryl monolaurate, corn oil, cotton seed oil or sunflower seed oil.

15. A device as claimed in claim 13, wherein the surfactant is oleyl alcohol.
15

16. A device as claimed in any of the preceding claims, wherein the pharmaceutically active agent is insoluble, or only sparingly soluble in liquified HFC-134a or HFC-227.

- 20 17. A device as claimed in claim 1, wherein the pharmaceutically active agent is selected from:-

- (1) steroid drugs such as, for example, beclomethasone, betamethasone, dexamethasone, fluticasone, hydrocortisone, budesonide, flunisolide, triamcinolone flumethasone, and prednisolone;

- (2) antibiotic and antibacterial agents such as, for example, neomycin, mupirocin and chlorhexidine;
- (3) systemically active drugs such as, for example, isosorbide dinitrate, isosorbide mononitrate, apomorphine and nicotine;
- 5 (4) antihistamines such as, for example, azelastine, chlorpheniramine, astemizole and terfenadine;
- (5) anti-inflammatory agents such as, for example, piroxicam, nedocromil, cromoglycate, fasafungine and iodoxamide;
- (6) anticholinergic agents such as, for example, ipratropium
10 bromide and oxitropium bromide;
- (7) anti-emetics such as, for example, domperidone, hyoscine, cinnarizine metoclopramide, cyclizine, dimenhydrinate and promethazine;
- (8) hormonal drugs such as, for example, vasopressin or
15 desmopressin;
- (9) bronchodilators, such as salbutamol, fenoterol and salmeterol;
- (10) sympathomimetic drugs, such as tramazoline and xylometazoline;
- (11) Anti-fungal drugs such as miconazole;
- 20 (12) Local anaesthetics such as benzocaine and lignocaine; and
- (13) pharmaceutically acceptable salts of any of the foregoing.

18. A device as claimed in claim 17, wherein the active agent is beclomethasone dipropionate.

19. A device as claimed in claim 17, wherein the beclomethasone dipropionate is in an anhydrous, hydrated, or solvated state, preferably, in an anhydrous state.
- 5 20. A device as claimed in any of the preceding claims, wherein the composition comprises HFC-134a as a propellant.
21. A device as claimed in any of the preceding claims substantially free of weak organic or strong inorganic acid.
- 10 22. A device as claimed in claim 16, wherein the solubility of the active agent in liquified HFC-134a or HFC-227 is from 3-0.001% w/v, preferably from 1-0.01% w/v.
- 15 23. A device as claimed in any of the preceding claims, wherein the valve means includes at least one component formed from a polyester.
24. A device as claimed in claim 23, wherein two relatively moveable, preferably mutually slidable, valve components are formed from a polyester.
- 20 25. A device as claimed in claim 23, wherein said component is a metering chamber.
26. A device as claimed in claim 23, wherein said component is a valve

core.

27. A device as claimed in any of the preceding claims, wherein the container includes a canister body comprising a polyester.

5

28. A device as claimed in claim 27, wherein the canister body is formed from metal lined with the polyester.

29. A device as claimed in any of the preceding claims, wherein said

10 portion is a canister cap or lining.

30. A device as claimed in any of the preceding claims, wherein the polyester is a polyalkylene benzene dicarboxylate.

15 31. A device as claimed in claim 30, wherein the polyester is a polyalkylene terephthalate.

32. A device as claimed in claim 31, wherein the polyester is a polybutylene terephthalate.

20

33. A device as claimed in any of the preceding claims, wherein the composition further comprises a flavouring oil, preferably peppermint oil Ph Eur.

34. A device as claimed in any of the preceding claims, wherein the pharmaceutical composition includes a solution of the pharmaceutically active agent in liquified HFC-134a or HFC-227, with the carrier as a co-solvent.

5 35. A device as claimed in claim 34 wherein the co-solvent solubilises the pharmaceutically active agent.

36. A device as claimed in claim 34 or claim 35, wherein substantially all of the pharmaceutically active agent present in the pharmaceutical
10 composition is dissolved in the propellant and co-solvent.

37. A device as claimed in any of claims 1-35, wherein a proportion of the pharmaceutically active agent present in the pharmaceutical composition is dissolved in the propellant and co-solvent, with the remainder being in
15 suspension.

38. A device as claimed in any of claims 1-36, wherein the composition comprises HFC-134a, beclamethasone dipropionate and ethanol.

20 39. Use of a polyester in contact with a composition as defined in any of claims 1-23.

40. A use as claimed in claim 38, wherein the polyester is as defined in any one of claims 30-32.

1 / 1




FIG. 1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/03360

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/72 B65D83/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K B65D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 32345 A (ASHURST IAN C ; LI LI (US); HERMAN CRAIG S (US); RIEBE MICHAEL T (U) 17 October 1996	1-4, 16-24, 34, 36, 38
Y	see abstract see page 3, line 7-24 see page 4, line 1-7 see page 5, line 6-14 see page 5, line 27-30 see page 6, line 8-14 see examples 8-22 see claims 1, 3, 4, 6, 12 ---	5-8, 12-15

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 March 1998

Date of mailing of the international search report

02/04/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

La Gaetana, R

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/03360

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 518 601 A (SCHERING CORP) 16 December 1992 see abstract see page 3, line 10 - page 4, line 30 see page 5, line 29 see examples 19-21,25 see examples 28-32 see claims ----	5-7, 12-14
Y	EP 0 626 173 A (ADIR) 30 November 1994 see abstract see examples see claims ----	8
Y	EP 0 234 500 A (RORER PHARMACEUTICAL CORP) 2 September 1987 see page 3, line 1 - page 5, line 21 see claim 7 ----	15
P,X	WO 97 09034 A (BIOGLAN LAB LTD ;GOODMAN MICHAEL (GB)) 13 March 1997 see the whole document ----	1-4, 9-11,13, 20,21, 23-33, 35,36, 39,40
A	WO 92 06675 A (MINNESOTA MINING & MFG) 30 April 1992 see abstract see page 2, line 19-30 see page 5, line 4-19 see claim 1 -----	38

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 97/03360

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9632345 A	17-10-96	AU 5481296 A EP 0820414 A NO 974738 A	30-10-96 28-01-98 11-12-97
EP 0518601 A	16-12-92	AT 132368 T AU 2178992 A CA 2111003 A CN 1067579 A CZ 9302713 A DE 69207409 D EP 0587790 A EP 0656205 A EP 0653205 A HU 67445 A JP 6508149 T MX 9202751 A NO 934499 A OA 9827 A SK 140593 A WO 9222287 A	15-01-96 12-01-93 23-12-92 06-01-93 13-07-94 15-02-96 23-03-94 07-06-95 17-05-95 28-04-95 14-09-94 01-12-92 09-12-93 15-04-94 09-11-94 23-12-92
EP 0626173 A	30-11-94	FR 2705570 A AT 145824 T AU 675303 B AU 6326094 A CA 2124179 A DE 69401030 D DE 69401030 T ES 2097618 T JP 7053354 A NZ 260586 A US 5431902 A ZA 9403648 A	02-12-94 15-12-96 30-01-97 01-12-94 26-11-94 16-01-97 15-05-97 01-04-97 28-02-95 27-06-95 11-07-95 15-02-95
EP 0234500 A	02-09-87	AU 6907687 A JP 62205023 A	20-08-87 09-09-87
WO 9709034 A	13-03-97	AU 6882796 A CA 2213774 A	27-03-97 13-03-97

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/GB 97/03360

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9206675 A	30-04-92	AT 114112 T	15-12-94
		AU 658854 B	04-05-95
		AU 9087391 A	20-05-92
		CA 2094266 A	19-04-92
		DE 69105212 D	22-12-94
		DE 69105212 T	23-03-95
		EP 0553298 A	04-08-93
		ES 2064160 T	16-01-95
		JP 6501710 T	24-02-94
		MX 9203481 A	01-07-92
		NZ 240237 A	27-06-94